Whalesbook
📉 The Financial Deep Dive
Procter & Gamble Health Limited announced its Q3 FY26 financial results, showcasing a significant topline expansion overshadowed by a sharp decline in profitability. Revenue from operations surged by a robust 20.7% YoY to ₹37,386 lakhs (₹373.86 Cr) for the quarter ended December 31, 2025. Total income mirrored this growth, rising 20.5% YoY to ₹37,822 lakhs.
However, the cost base expanded alarmingly. Total expenses jumped 40.3% YoY to ₹26,940 lakhs. This surge was primarily fueled by a 37.1% YoY increase in the cost of materials consumed, a 31.4% YoY rise in employee benefits expenses, and a substantial 44.4% YoY increase in other expenses. This significant cost inflation directly impacted profitability.
Profit Before Tax (PBT) for the quarter saw a 10.6% YoY decline to ₹10,882 lakhs. Net Profit for Q3 FY26 fell by 14.6% YoY to ₹7,759 lakhs (₹77.59 Cr), down from ₹9,090 lakhs in the same period last year. The diluted Earnings Per Share (EPS) before exceptional items contracted to ₹46.74 from ₹54.76 in Q3 FY25.
Nine-Month Performance:
For the nine-month period ended December 31, 2025, revenue from operations showed a healthy 14.4% YoY growth, reaching ₹103,752 lakhs (₹1,037.52 Cr). Net profit for the nine months increased by 22.3% YoY to ₹23,231 lakhs (₹232.31 Cr). It's important to note that this growth is partly attributable to the absence of an exceptional item of ₹2,019 lakhs recorded in the prior year's nine-month period, which was related to the sale of assets of an injection plant and impairment.
Dividend Announcement:
The Board of Directors declared an interim dividend for FY2025-26 of ₹160 per equity share. This includes a one-time special dividend of ₹50 per share, intended to reward shareholders. The dividend is scheduled to be paid on or before March 4, 2026.
🚩 Risks & Outlook
The primary concern arising from this report is the significant margin compression witnessed in the third quarter due to escalating expenses, particularly in raw materials and operational costs. While revenue growth remains strong, investors will be looking for management's strategy to control costs and protect margins in the upcoming quarters. The full-year outlook remains uncertain without explicit guidance, but the Q3 performance highlights the challenges of managing an expanding cost base in a competitive environment. The company operates in the Pharmaceuticals segment, where input cost volatility can have a direct impact on margins.